Nautilus Biotechnology Inc Dossier
Qualitative Analysis
Business overview
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) is a development-stage life sciences company pioneering a single-molecule proteome analysis platform. The company's core technology, the Nautilus Voyager platform, integrates breakthrough innovations in computer science, engineering, and biochemistry to deliver extreme sensitivity and scale in quantifying the human proteome. Its proprietary method, Iterative Mapping of Proteoforms (IMaP), utilizes multiaffinity antibodies to iteratively probe single-protein molecules and their variants, providing a quantitative measurement of proteoform diversity. The end-to-end platform comprises the Voyager instrument, reagent consumables (flow cells, sample preparation kits, and affinity reagent probes), and cloud-based machine learning analysis software delivered as a SaaS.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Launched in January 2026, the EAP allows select academic, nonprofit, and biopharma partners to engage with the Nautilus Voyager platform and generate high-resolution proteomic data. The program began with the Tau proteoform assay and is expanding to include oncology and Parkinson's disease targets.
Expected impact: Fosters early adoption, generates peer-reviewed publications, and builds a pipeline of validated customer use cases to support the full commercial launch.
Development of a next-generation broadscale assay format designed to improve probe compatibility, performance, and long-term scalability, enabling the platform to measure at least 10,000 to 11,000 proteins per sample.
Expected impact: Positions the Voyager platform as a highly competitive, high-throughput alternative to mass spectrometry and existing affinity-based technologies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Baylor is the first customer for the Voyager platform under the EAP. The NIH-funded project leverages single-molecule proteomics to develop a computational multi-omics toolkit for high-resolution cancer isoform analysis.
Terms: Not disclosed; funded by an NIH grant.
A high-impact collaboration to study the connection between the alpha-synuclein protein and Parkinson's disease, expanding the Voyager platform's proteoform roadmap beyond Tau.
Terms: Supported by a $1.6 million research grant from the Michael J. Fox Foundation, with $1.2 million allocated to Nautilus.